$4.10
0.9128.53%
At Close: -
$4.00
-0.1-2.44%
After Hours: 6:39 PM EDT
15 minutes delayed
Relmada Therapeutics
RLMDNASDAQ
Relmada Therapeutics (NASDAQ:RLMD) Stock, Analyst Ratings, Price Targets, Forecasts
Relmada Therapeutics Inc has a consensus price target of $15.17 based on the ratings of 12 analysis. The 3 most-recent analyst ratings were released by Goldman Sachs, Mizuho, and SVB Leerink on June 5, 2024, June 15, 2023, and January 23, 2023, respectively. With an average price target of $12.67 between Goldman Sachs, Mizuho, and SVB Leerink, there's an implied 216.67% upside for Relmada Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Goldman Sachs
Mizuho
SVB Leerink
Guggenheim
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Relmada Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/05/2024 | Buy Now | -50% | Goldman Sachs | Andrea Tan | $3 → $2 | Downgrade | Neutral → Sell | Get Alert |
| 06/15/2023 | Buy Now | 550% | Mizuho | Vamil Divan | → $26 | Reiterates | Buy → Buy | Get Alert |
| 01/23/2023 | Buy Now | 150% | SVB Leerink | Marc Goodman | $42 → $10 | Maintains | Outperform | Get Alert |
| 10/14/2022 | Buy Now | 100% | Goldman Sachs | Andrea Tan | → $8 | Downgrade | Buy → Neutral | Get Alert |
| 10/14/2022 | Buy Now | — | Guggenheim | Yatin Suneja | — | Downgrade | Buy → Neutral | Get Alert |
| 10/13/2022 | Buy Now | — | Oppenheimer | Jay Olson | — | Downgrade | Outperform → Perform | Get Alert |
| 09/23/2022 | Buy Now | 1925% | Goldman Sachs | Andrea Tan | $49 → $81 | Maintains | Buy | Get Alert |
| 09/06/2022 | Buy Now | 1400% | Guggenheim | Yatin Suneja | $50 → $60 | Maintains | Buy | Get Alert |
| 05/09/2022 | Buy Now | 1500% | Oppenheimer | Jay Olson | $75 → $64 | Maintains | Outperform | Get Alert |
| 03/24/2022 | Buy Now | 1225% | Goldman Sachs | Ross Weinreb | $69 → $53 | Maintains | Buy | Get Alert |
| 12/20/2021 | Buy Now | 950% | SVB Leerink | Marc Goodman | — | Maintains | Outperform | Get Alert |
| 11/18/2021 | Buy Now | 1150% | Mizuho | Vamil Divan | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Relmada Therapeutics (RLMD) stock?
The latest price target for Relmada Therapeutics (NASDAQ:RLMD) was reported by Goldman Sachs on June 5, 2024. The analyst firm set a price target for $2.00 expecting RLMD to fall to within 12 months (a possible -50.00% downside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Relmada Therapeutics (RLMD)?
The latest analyst rating for Relmada Therapeutics (NASDAQ:RLMD) was provided by Goldman Sachs, and Relmada Therapeutics downgraded their sell rating.
When was the last upgrade for Relmada Therapeutics (RLMD)?
There is no last upgrade for Relmada Therapeutics
When was the last downgrade for Relmada Therapeutics (RLMD)?
The last downgrade for Relmada Therapeutics Inc happened on June 5, 2024 when Goldman Sachs changed their price target from $3 to $2 for Relmada Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Relmada Therapeutics (RLMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Relmada Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Relmada Therapeutics was filed on June 5, 2024 so you should expect the next rating to be made available sometime around June 5, 2025.
Is the Analyst Rating Relmada Therapeutics (RLMD) correct?
While ratings are subjective and will change, the latest Relmada Therapeutics (RLMD) rating was a downgraded with a price target of $3.00 to $2.00. The current price Relmada Therapeutics (RLMD) is trading at is $4.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.